COST-EFFECTIVENESS OF TRANSFERRING TYPE 2 DIABETIC PATIENTS FROM NEUTRAL PROTAMINE HAGEDORN (NPH) TO DETEMIR IN PORTUGAL SETTINGS

被引：0
|
作者：
Carvalho, D. [1 ]
Lindner, L. [2 ]
Kozarzewski, M. [3 ]
机构：
[1] Sao Joao Hosp, Oporto, Portugal
[2] IMS Hlth, Barcelona, Cataluna, Spain
[3] Novo Nordisk Portugal, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1348
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A479 / A480
页数：2
相关论文
共 50 条
  • [31] Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database
    Laubner, K.
    Molz, K.
    Kerner, W.
    Karges, W.
    Lang, W.
    Dapp, A.
    Schuett, M.
    Best, F.
    Seufert, J.
    Holl, R. W.
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (05) : 395 - 404
  • [32] Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH
    Valentine, William J.
    Palmer, Andrew J.
    Erny-Albrecht, Katrina M.
    Ray, Joshua A.
    Cobden, David
    Foos, Volker
    Lurati, Francisco M.
    Roze, Stephane
    [J]. ADVANCES IN THERAPY, 2006, 23 (02) : 191 - 207
  • [33] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
    Ray, J. A.
    Valentine, W. J.
    Goodall, G.
    Aagren, M.
    Kotchie, R. W.
    [J]. DIABETOLOGIA, 2007, 50 : S428 - S428
  • [34] Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH
    William J. Valentine
    Andrew J. Palmer
    Katrina M. Erny-Albrecht
    Joshua A. Ray
    David Cobden
    Volker Foos
    Francisco M. Lurati
    Stéphane Roze
    [J]. Advances in Therapy, 2006, 23 : 191 - 207
  • [35] SHORT-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH INSULIN IN INSULIN-NAIVE SUBJECTS WITH TYPE 2 DIABETES IN SWEDEN
    Ridderstrale, M.
    Ericsson, A.
    Jensen, M. M.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A480 - A480
  • [36] Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
    Rosenstock, J.
    Fonseca, V.
    McGill, J. B.
    Riddle, M.
    Halle, J. P.
    Hramiak, I.
    Johnston, P.
    Davis, M.
    [J]. DIABETOLOGIA, 2009, 52 (09) : 1971 - 1973
  • [37] The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy
    Rodby, RA
    Chiou, CF
    Borenstein, J
    Smitten, A
    Sengupta, N
    Palmer, AJ
    Roze, S
    Armemans, L
    Simon, TA
    Chen, RS
    Lewis, EJ
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (07) : 2102 - 2119
  • [38] COST-EFFECTIVENESS OF USING DETEMIR IN TYPE 2 DIABETES WITH THE RISK OF CARDIOVASCULAR EVENTS AND DEATH
    Romero, M.
    Chavez, D.
    Karpf, E.
    Alvis, N.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A547 - A547
  • [39] Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
    J. Rosenstock
    V. Fonseca
    J. B. McGill
    M. Riddle
    J. P. Hallé
    I. Hramiak
    P. Johnston
    M. Davis
    [J]. Diabetologia, 2009, 52 : 1971 - 1973
  • [40] BIPHASIC INSULIN ASPART 30 VS. NPH PLUS REGULAR HUMAN INSULIN IN TYPE 2 DIABETIC PATIENTS: A COST-EFFECTIVENESS STUDY
    Farshchi, A.
    Oskuee, M.
    Rashed, M.
    Aghili, R.
    Kebriaeezadeh, A.
    Esteghamati, A.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 : A90 - A91
12345